Floatz logo

Bxcl501

Agitation,Psychomotor

Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de MontrealPhase 4 / ApprovedActive
A
80/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
70/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Agitation,Psychomotor cohort.

Asset / SponsorPhaseRating
Axs-05
Axsome Therapeutics, Inc.
Phase 3BB
Wellbutrin
Axsome Therapeutics, Inc.
Phase 2/3B
Igc Ad1
IGC Pharma, LLC
Phase 2CCC
Low THC
Mclean Hospital
Early Phase 1C
Marijuana
M. H MediCane Ltd.
N/AD
Loxapine
Wake Forest University Health Sciences
D

Same molecule, other indications

Bxcl501 is also rated in:

Pain, ChronicDormant
A
Indicative ·
80 / 100
View asset →
schizophreniform disorderDormant
A
Indicative ·
80 / 100
View asset →
schizoaffective disorderDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →